FDG-PET comparative effectiveness data sought by AHCPR in ongoing technology review.
FDG-PET MEDICARE TECHNOLOGY ASSESSMENT: AHCPR SEEKS SCIENTIFIC DATA on use of the imaging modality "as a diagnostic and management tool for use in patients with focal or partial epilepsy," the Agency for Health Care Policy & Research said in an Aug. 14 Federal Register notice. The ongoing evaluation of fluorodeoxyglucose positron emission tomography imaging will form the basis of the Health Care Financing Administration's Medicare coverage decision on the technology.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth